Sign in
CompletedPhase 4

Optimizing Dosing Strategies in Oral Iron Supplementation

Key facts

Who runs it
Luzerner Kantonsspital
Where
Switzerland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
29 people enrolled
Started
1 Mar 2024
Ended
18 Nov 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Tardyferon
Record updated
7 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Informed Consent signed by the subject
  • ≥18 years of age
  • Iron deficiency: Ferritin <30 µg/l
  • hemoglobin ≥ 80 g/l
  • CRP < 5 mg/l

Who cannot take part

  • Oral or intravenous iron supplementation <12 weeks prior to investigation
  • Blood transfusion or donation <12 weeks prior to investigation
  • Active chemotherapy
  • Contraindications to intervention medication (Tardyferon), e.g. known hypersensitivity or allergy to iron sulfate / ferrous sulfate
  • Inability to follow the procedures of the investigation, e.g. due to language problems, psychological disorders, dementia, etc. of the subject; Note; Due to slow recruitment, the following inclusion criterion was removed on 09/25/2024 (MM/DD/YYYY):; Anemia (as defined by the WHO): Hemoglobin <130 g/L for men, Hemoglobin <120 g/l for women, Hemoglobin <110 g/l for pregnant women
  • Refusal of study participation,
  • Regular administration of Erythropoietin

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this clinical trial is to evaluate, if a change in dosing strategy in oral iron supplementation from leads to an improvement of iron absorption and consequently a faster therapy in patients with iron deficiency.

Read full original descriptionShow less

The main question the study aims to answer is: Does a treatment effect (measured by change in hemoglobin after 12 weeks of treatment) exist between daily oral iron supplementation and interval administration (every second day)? Participants will receive oral iron supplementation every second day with double the standard dose (intervention group). Researchers will compare this group with the active control group, that receives oral iron supplementation every day with the standard dose.

Participants will present for three patient visits (at baseline, after 6 and after 12 weeks of treatment).

The 2 groups in the trial

  • Intervention GroupTreatment being tested

    Oral iron supplementation with Eisen-II-Sulfat (Tardyferon ®) Every second day 2 x 80 mg Tardyferon® for a duration of 12 weeks.

    Treatment: Tardyferon

  • Active ControlExisting treatment, for comparison

    Oral iron supplementation with Eisen-II-Sulfat (Tardyferon ®) Every day 1x 80 mg Tardyferon® for a duration of 12 weeks

    Treatment: Tardyferon

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Record updated
7 January 2026